Matinas BioPharma Holdings (MTNB) Common Equity (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Common Equity data on file, last reported at $3.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $3.0 million, down 51.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (down 51.8% YoY), and the FY2025 annual result was $4.8 million, down 36.36% from the prior year.
• Common Equity eased to $3.0 million in Q1 2026 per MTNB's latest filing, from $4.8 million in the prior quarter.
• Over five years, Common Equity peaked at $47.7 million in Q1 2022 and troughed at $3.0 million in Q1 2026.
• A 5-year average of $20.8 million and a median of $19.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity declined 28.36% in 2022, then plunged 60.56% in 2024.
• A 5-year view of Common Equity shows it stood at $36.6 million in 2022, then sank by 47.47% to $19.2 million in 2023, then sank by 60.56% to $7.6 million in 2024, then plunged by 36.36% to $4.8 million in 2025, then sank by 37.43% to $3.0 million in 2026.
• Business Quant data shows MTNB's Common Equity at $3.0 million in Q1 2026, $4.8 million in Q4 2025, and $6.5 million in Q3 2025.